TSH-receptor antibodies (IgG) in Graves' disease bind and activate TSH-R, stimulating thyroid growth and excessive T3/T4 secretion without negative feedback. Immune infiltration and thyroid-associated orbitopathy (from cross-reactive antigens on orbital fibroblasts) distinguish Graves' from other causes of hyperthyroidism.
To understand Graves' disease, begin with normal thyroid regulation. The hypothalamus releases TRH, which signals the pituitary to release TSH, which binds TSH receptors on thyroid follicular cells to stimulate T3 and T4 production. When T3 and T4 levels rise, they inhibit both TRH and TSH via negative feedback—a classic closed-loop control system. Graves' disease is a breakdown of this feedback caused by the immune system producing antibodies that mimic TSH's activating signal without being subject to the same regulatory constraints.
Thyroid-stimulating immunoglobulins (TSI), also called TSH-receptor antibodies (TRAb), are IgG autoantibodies generated by autoreactive B cells. You know from the adaptive immune response that IgG antibodies are durable, high-affinity molecules produced during the late adaptive response. Here, autoreactive T helper cells that escape central tolerance activate B cells to produce IgG targeting the TSH receptor. These antibodies bind to TSH-R and activate it continuously—because unlike TSH itself, they are not cleared by normal regulatory mechanisms and are not subject to the pituitary's feedback suppression. The result is persistent, unregulated stimulation: the thyroid grows (goiter) and T3/T4 levels rise without a ceiling.
The consequences of chronically elevated thyroid hormone follow from T3/T4's metabolic roles: increased basal metabolic rate, enhanced adrenergic sensitivity (producing tachycardia, hypertension, tremor, and anxiety), accelerated bone turnover, and heat intolerance. These symptoms are shared with any cause of hyperthyroidism. What distinguishes Graves' are two immune-mediated features unique to this disease. The first is thyroid-associated orbitopathy (TAO): orbital fibroblasts express TSH receptors and IGF-1 receptors; the same autoantibodies cross-react with these antigens, triggering inflammatory expansion of orbital fat and extraocular muscles, producing the characteristic exophthalmos (proptosis). The second is pretibial myxedema: glycosaminoglycan deposition in the skin of the lower legs driven by similar fibroblast stimulation.
Treatment targets hormone production (antithyroid drugs like methimazole block synthesis; radioactive iodine ablates thyroid tissue; surgery removes the gland) or downstream adrenergic effects (beta-blockers for symptomatic relief). None of these address the underlying autoimmunity directly, which is why relapse after stopping antithyroid drugs is common and why definitive treatment (ablation or surgery) is often preferred in patients who do not achieve lasting remission.